PPARs and LXRs: Atherosclerosis goes nuclear

Trends in Endocrinology and Metabolism

Volumn 15, Issue 4, 2004, Pages 158-165

  Barish, Grant D ^a,b   Evans, Ronald M ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ANTILIPEMIC AGENT; CELL NUCLEUS RECEPTOR; CLOFIBRATE; FENOFIBRATE; GLUCOSE; ISOPROTEIN; LIGAND; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; TROGLITAZONE;

ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; HUMAN; INFLAMMATION; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DNA-BINDING PROTEINS; HUMANS; ISOMERISM; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 1942422103     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2004.03.003     Document Type: Review

References (68)

1. Glass C., et al. Atherosclerosis: the road ahead. Cell. 104:2001;503-516.
2. Weitz-Schmidt G. Statins as anti-inflammatory agents. Trends Pharmacol. Sci. 23:2002;482-486.
3. Chawla A., et al. Nuclear receptors and lipid physiology: opening the X-files. Science. 294:2001;1866-1870.
4. Lee C., et al. Transcriptional repression of atherogenic inflammation: modulation by PPARδ Science. 302:2003;453-457.
5. Wagner B., et al. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell. Biol. 23:2003;5780-5789.
6. Braissant O., et al. Differential expression of peroxisome proliferators-activated receptors: tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat. Endocrinology. 137:1999;354-366.
7. Ziouzenkova O., et al. Lipolysis of triglyceride-rich lipoproteins generates PPAR ligands: Evidence for an anti-inflammatory role for lipoprotein lipase. Proc. Natl. Acad. Sci. U. S. A. 100:2003;2730-2735.
8. Lee S., et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol. 15:1995;3012-3022.
9. Kersten S., et al. Peroxisome proliferators-activated receptor α mediates the adaptive response to fasting. J. Clin. Invest. 103:1999;1489-1498.
10. Guerre-Millo M., et al. PPAR-α-null mice are protected from high-fat diet-induced insulin resistance. Diabetes. 50:2001;2809-2814.
11. Tordjman K., et al. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107:2001;1025-1034.
12. Haluzik M., et al. PPAR-α deficiency does not alter insulin sensitivity in mice maintained on regular or high fat diet: the hyperinsulinemic-euglycemic clamp studies. Endocrinology. 144:2003;1662-1667.
13. Chinetti G., et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J. Biol. Chem. 273:1998;25573-25580.
14. Chinetti G., et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7:2001;53-58.
15. Plutzky J. Peroxisome proliferators-activated receptors in endothelial cell biology. Curr. Opin. Lipidol. 12:2001;511-518.
16. Tordjman K., et al. PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice. J. Clin. Invest. 107:2001;1025-1034.
17. Fu T., et al. The peroxisome-proliferator-activated receptor α agonist ciprofibrate severely aggravates hypercholesterolemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373:2003;941-947.
18. Duez H., et al. Reduction of atherosclerosis by the peroxisome proliferator-activated receptor α agonist fenofibrate in mice. J. Biol. Chem. 277:2002;48051-48057.
19. Robins S., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events. J. Am. Med. Assoc. 285:2001;1585-1591.
20. Syvanne M., et al. Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. Circulation. 98:1998;1993-1999.
21. Forman B., et al. Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell. 83:1995;803-812.
22. Lehmann J., et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:1995;12953-12956.
23. Barroso I., et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus, and hypertension. Nature. 402:1999;880-883.
24. Barak Y., et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell. 4:1999;585-595.
25. Rosen E., et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4:1999;611-617.
26. Kubota N., et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:1999;597-609.
27. He W., et al. Adipose-specific peroxisome proliferators-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U. S. A. 100:2003;15712-15717.
28. Gavrilova O., et al. Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278:2003;34268-34276.
29. Matsusue K., et al. Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111:2003;737-747.
30. Norris A., et al. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J. Clin. Invest. 112:2003;608-618.
31. Hevener A., et al. Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9:2003;1491-1497.
32. Lee C., Evans R.M. Peroxisome proliferators-activated receptor-γ in macrophage lipid homeostasis. Trends Endocrinol. Metab. 13:2002;331-335.
33. Welch J., et al. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100:2003;6712-6717.
34. Haffner S., et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 106:2002;679-684.
35. Satoh N., et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care. 26:2003;2493-2499.
36. Peters J.F., et al. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator- activated receptor β Mol. Cell. Biol. 20:2000;5119-5128.
37. Barak Y., et al. Effects of peroxisome proliferators-activated receptor γ on placentation, adiposity, and colorectal cancer. Proc. Natl. Acad. Sci. U. S. A. 99:2002;303-308.
38. Oliver W., et al. A selective peroxisome proliferators-activated receptor γ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5306-5311.
39. Leibowitz M., et al. Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett. 473:2000;333-336.
40. Tanaka T., et al. Activation of peroxisome proliferators-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl. Acad. Sci. U. S. A. 100:2003;15924-15929.
41. Wang Y., et al. Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell. 113:2003;159-170.
42. Dressel U., et al. The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol. Endocrinol. 17:2003;2477-2493.
43. Vosper H., et al. The peroxisome proliferator-activated receptor δ promotes lipid accumulation in human macrophages. J. Biol. Chem. 276:2001;44258-44265.
44. Chawla A., et al. PPARδ is a very low-density lipoprotein sensor in macrophages. Proc. Natl. Acad. Sci. U. S. A. 100:2003;1268-1273.
45. Tan N. Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes Dev. 15:2001;3263-3277.
46. Janowski B., et al. An oxysterol signaling pathway by the nuclear receptor LXR alpha. Nature. 383:1996;728-731.
47. Alberti S., et al. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J. Clin. Invest. 107:2001;565-573.
48. Tontonoz P., et al. Liver x receptor signaling pathways in cardiovascular disease. Mol. Endocrinol. 17:2003;985-993.
49. Schuster G., et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation. 106:2002;1147-1153.
50. Venkateswaran A., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRα Proc. Natl. Acad. Sci. U. S. A. 97:2000;12097-12102.
51. Yu L., et al. Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8. J. Biol. Chem. 278:2003;15565-15570.
52. Laffitte B., et al. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. U. S. A. 98:2001;507-512.
53. Repa J., et al. Regulation of mouse sterol regulatory element-binding protein-1c (SREBP-1c) by oxysterol receptors, LXRa and LXRb. Genes Dev. 14:2000;2819-2830.
54. Schultz J., et al. Role of LXRs in control of lipogenesis. Genes Dev. 14:2000;2831-2838.
55. Cao G., et al. Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 278:2003;1131-1136.
56. Dalen K., et al. Expression of the insulin-responsive glucose transporter glut4 in adipocytes is dependent on liver X receptor α J. Biol. Chem. 278:2003;48283-48291.
57. Repa J., et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science. 289:2000;1524-1529.
58. Joseph S., et al. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9:2003;213-219.
59. Castrillo A., et al. Crosstalk between LXR and toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell. 12:2003;805-816.
60. Libby P., et al. Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation. 96:1997;4095-4103.
61. Tangirala R., et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11896-11901.
62. Joseph S., et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U. S. A. 99:2002;7604-7609.
63. Terasaka N., et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536:2003;6-11.
64. Li A., et al. Peroxisome proliferators-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106:2000;523-531.
65. Claudel T., et al. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. U. S. A. 98:2001;2610-2615.
66. Chen Z., et al. Troglitazone inhibits atherosclerosis in apolipoprotein e-knockout mice. Arterioscler. Thromb. Vasc. Biol. 21:2001;372-377.
67. Collins A., et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21:2001;365-371.
68. Chawla A., et al. A PPARg-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7:2001;161-171.